Cantor Fitzgerald Reiterates VYNE Therapeutics (VYNE) at Overweight with $10 PT, Sees Latest FMX114 Data Underscoring "Positive Investment Thesis"
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
- Nasdaq ends higher as AI heavyweights rebound ahead of midterm results
- Apple shares slip amid guidance for tightening margins, slowing services growth
- Rising shorts cool U.S. large-cap positioning, cutting liquidation risk: Citi
- Apple's 'unprecedented' memory warning adds fuel to wobbly Micron, SK hynix trade
- Palantir raises 2026 revenue outlook after quarterly revenue nearly doubles on AI
| (NASDAQ: VYNE) | Delayed: 28.56 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $28.56 | 52 Week High | $ | |||
| Open | $28.56 | 52 Week Low | $ | |||
| Day High | $28.56 | P/E | N/A | |||
| Day Low | $28.56 | EPS | $ | |||
| Volume | 52,066 | |||||
